UGA & Manus Among Awardees in $214M BioMADE Investment

BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

With funding from the U.S. Department of War and the U.S. National Science Foundation, these projects will support the production of critically needed goods and materials, strengthen the domestic supply chain, and build a 21st century workforce.


MINNEAPOLIS-ST. PAUL, MN/EMERYVILLE, CA, April 29, 2026 – Today, BioMADE announced 14 cutting-edge new projects that will support the growth and development of the U.S. bioindustrial manufacturing industry. These projects will support the manufacture of innovative bio-based products like a lithium biosorbent for biomining; plastics for 3D printing; proteins for wound healing and chemical defense; biosensors for disease detection; and more. They will leverage state-of-the-art methodologies like machine learning, AI, and advanced new sensors and purification systems. Projects will also support the development of the needed biomanufacturing workforce through projects that are easing the transition for veterans into civilian careers, launching community college programs, and developing hands-on apprenticeship programs. 


“Global competition for bioindustrial manufacturing is at a critical tipping point, with many countries around the world investing heavily in biotechnology innovation and commercialization. If the U.S. is to remain competitive, we must do the same,” said Douglas Friedman, Chief Executive Officer at BioMADE. “We appreciate U.S. Department of War and the National Science Foundation’s continued support for domestic biomanufacturing and their steadfast commitment to establishing the U.S. as a global leader in the 21st century bioeconomy through BioMADE." 


These projects represent a shared investment of over $21 million across 23 different member organizations that are located across the country – from the coasts to the heartland – highlighting the breadth and depth of the rapidly growing U.S. bioeconomy. 


"BioMADE's newest projects showcase the dual importance of bioindustrial manufacturing and its benefits to both the commercial and defense sectors," said Stephen Recchia, Program Manager for the Department of War Manufacturing Innovation Institutes. "Bioindustrial manufacturing has the power to secure domestic supply chains for essential chemicals and materials, enhance national security by reducing reliance on foreign inputs, and enable point-of-need manufacturing for warfighters." 


For the first time, some of these projects are funded through a partnership with the National Science Foundation, which will support initial efforts from the basic research through proof-of-concept, with BioMADE supporting technology maturation, risk reduction, and scale-up aspects of each integrated project. 


"Fundamental biological and biomanufacturing research supported by NSF has led to advances in health, food, fuels and chemicals," said Susan Marqusee, NSF Assistant Director for Biological Sciences. "These new projects build on NSF's long-term investment and help us to further economic growth in industrial biotechnology — a sector that contributes over $200 billion to the U.S. economy." 


"By connecting academic researchers with BioMADE's industry members, this public-private collaboration will help realize the potential of fundamental science and engineering research for food, health, chemicals and materials," said Don Millard, head of the NSF Directorate for Engineering. "This partnership will allow researchers to investigate new ideas for biomanufacturing, test and improve new methods at scale, and ultimately make biotechnology advances widely available." 


“We’re grateful to the National Science Foundation for their partnership and investment in these projects,” said Melanie Tomczak, Chief Technology Officer and Head of Programs at BioMADE. “BioMADE has always represented the power of collaboration, bringing together public, private, and government partners to enact change for the U.S. biomanufacturing industry. These projects are no different, and I look forward to seeing the wide-reaching effects that our members will have through this work.”   


Bioindustrial manufacturing uses biological systems to convert agricultural feedstocks and waste streams to high-value chemicals, materials, textiles, fuels and lubricants, bioplastics, composites, and other products for consumer and defense needs. Because bioindustrial manufacturing typically uses feedstocks such as corn, soy, and sugar beets, American farmers will benefit from the new markets created by BioMADE technologies, and rural communities will benefit from the manufacturing jobs creating the associated products.   


As the U.S. competes for global leadership in this growing industry, these new projects will move the needle by scaling up production of needed products, improving processes that span the industry, and building the needed workforce. 


Technology and Innovation Projects


6 projects | $4.6 million DoW funds | $2.2 million NSF funds | $4.8 million non-federal cost share   Federal funding from the U.S. Department of War and the U.S. National Science Foundation 


  • Optimizing Lithium Release and Recovery for Cost-Effective Biomining Processes – This project will develop and validate a scalable microbial process for extracting lithium from produced water, a lithium-rich industrial byproduct generated during oil and gas production. 
    Member: 
    AlkaLi Labs
  • Driving Cost Reduction in Biomanufacturing Biomaterials from Methane: Engineering Novel Strains to Increase Downstream Processing Efficiency – By increasing the efficiency of downstream processing, this project will reduce costs and improve overall process economics to produce PHA from methane gas for use in films, fibers, and 3D printing.   
    Member team: 
    Mango MaterialsUniversity of California, Davis
  • Development of Genomic Language Models to Predict Optimal Genomes for Commercial Protein Production – This project will create a first-of-its-kind predictive AI model that will accelerate strain optimization for the production of resilient and cost-effective proteins capable of wound healing, advanced nutrition, chemical defense, or other defense-relevant compounds.
    Member team: 
    TriplebarUniversity of California, Berkeley
  • In-Fermenter Cell Datastreams: Wireless Networks of Free-Floating Microbial-Electronic Sensors – Using a network of in-bioreactor free-floating sensors, this project will generate a new type of datastream from industrial bioreactors to enable predictive artificial intelligence (AI) and machine learning (ML) for fermentation optimization.
    Member team: 
    Boston UniversityCapra Biosciences
  • Cell Cultured Chocolate – Through novel bioreactors, improved vessel and media sterilization methods, and in-line biomass sensors, this project will lower the production costs of high-quality chocolate products by using cacao plant cell culture.
    Member team: 
    University of California – DavisCalifornia Cultured
  • Low-Cost Nanobody-Based Growth Factor Replacements – This project will develop scalable, low-cost manufacturing methods for next-generation media additives that could enable distributed production and deployment for diagnostics and countermeasures in response to new disease outbreaks warfighters may be experiencing around the world, as well as protecting everyday Americans.   
    Member team: 
    Roke BiotechnologiesDuke University


Education and Workforce Development Projects


6 projects   $4.4 million federal funds   $5.2 million non-federal cost share   Federal funding from the U.S. Department of War 


  • How To Grow (Almost) Anything: A National Network for Enabling and Scaling EWD in Biomanufacturing – This project will train the next generation of bioindustrial manufacturing talent by creating and implementing a custom curriculum that will include hands-on lab modules, weekly lectures, and individual and network-wide final projects that reflect current and emerging needs in the bioindustrial manufacturing sector.
    Member: 
    Massachusetts Institute of Technology
  • Apprenticeship Framework for Pilot-Scale Bioindustrial Manufacturing Operator Training – By developing an apprenticeship training program for biomanufacturing operators in a pilot plant environment, this work will result in trained apprentices and a blueprint to translate the apprenticeship program to other facilities across the U.S.
    Member team: 
    ManusUniversity of Georgia
  • DESIGN of a Biomanufacturing EWD Prototype to Support the Growth of South Dakota's Bioeconomy – This pilot-scale biomanufacturing education and workforce development training program will create course content for people at all levels interested in a career in biomanufacturing, including veterans re-entering the civilian workforce.
    Member team: 
    Dakota BioWorxSouth Dakota Biotech
  • NC BioMISSION – After partnering with industry to build a robust curriculum, this project will launch an undergraduate certificate program, provide a capstone industry experience, and integrate data analytics, data science, and machine learning for biomanufacturing. 
    Member: 
    University of North Carolina, Greensboro
  • SPRINT: Scalable Protein Research for INnovative Training – This project will expand, implement, and publicly share a scalable biomanufacturing training model to prepare thousands of undergraduate students for careers in the bioindustrial manufacturing economy. 
    Member team: 
    University of California – DavisMiraCosta CollegeModesto Junior College
  • Strengthening the Life Science Talent Pipeline: Life Science Career Fellowship Personalized Cohort – By working with multiple community colleges in Los Angeles and the Bay Area, this project will provide comprehensive career preparation through personalized industry mentorship, professional development workshops, networking opportunities, and company tours.
    Member team: 
    Biocom Institute


Safety and Security Projects 


2 projects   $131,000 federal funds   $131,000 non-federal cost share   Federal funding from the U.S. Department of War 


  • Development of Biopesticide Life Cycle Analysis Resources – Researchers will create a comprehensive Life Cycle Assessment and Life Cycle Inventory Data Gap Framework for a representative biopesticide that will include critical data and tools to understand and reduce detrimental impacts throughout the bioproduct life cycle—from raw material sourcing to production and end use. 
    Member team: 
    Boundless Impact Research & Analytics,Invasive Species Corporation
  • Resilient Domestic Feedstocks for the U.S. Precision Fermentation Industry – This project will improve domestic bioindustrial manufacturing outcomes and increase its competitiveness through enhanced Life Cycle Assessments (LCA) of feedstocks. 
    Member: 
    Checkerspot


About BioMADE


BioMADE and its network of over 300 members across 40 states are strengthening American competitiveness, creating a more resilient supply chain, reshoring manufacturing jobs, producing biobased products without relying on foreign inputs, and building a globally competitive 21st century workforce. BioMADE is also launching a Pilot Plant Network of critically needed pilot-scale bioindustrial manufacturing facilities that will propel products out of the lab and into the commercial and defense markets. BioMADE was catalyzed by the U.S. Department of Defense in October of 2020 and is a proud member of Manufacturing USA®. Learn more about BioMADE at biomade.org.  


Source: https://www.biomade.org/news/biomade-announces-214-million-invested-in-14-projects

August 31, 2026
The White House, August 31, 2026 - ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). The agreements bring the total number of pharmaceutical manufacturers with MFN deals to 26, covering 89% of the branded drug market. The nine manufacturers are comprised of mid-sized pharmaceutical companies, including Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements reduce prices on drugs that treat numerous costly, chronic, and even rare diseases, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer. The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable. The agreements ensure foreign nations can no longer use price controls to freeride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market. Each of these manufacturers has agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients. BOLSTERING AMERICA’S PHARMACEUTICAL SUPPLY CHAINS AND RESERVES: These nine pharmaceutical manufacturers committed to invest at least $19.6 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the MFN agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency. UCB will contribute 163 tons of levetiracetam, an anticonvulsant used to control and prevent certain types of seizures, to the SAPIR. Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline; both antibiotics to treat bacterial infections, to the SAPIR. Teva Pharmaceuticals will contribute 45 metric tons of metronidazole, an antibiotic and antiprotozoal used to treat certain bacterial and parasitic infections, and 4.8 tons of amlodipine, an antihypertensive drug, to the SAPIR. Astellas will contribute 25 kg of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have had organ transplants, to the SAPIR. LOWERING COSTS FOR AMERICANS: President Trump’s decisive and historic actions are lowering drug prices for the American people. Since its February launch, patients have saved more than $700 million on medicines through TrumpRx, including massive discounts on some of the most popular and costly medications used to treat obesity and infertility. In July of 2026, senior citizens without access to GLP-1 coverage to treat obesity gained access for just $50 per month. In the two months since the launch of this program, over 500,000 seniors have saved a total of $216 million dollars on these life-changing medicines. The Council of Economic Advisers estimates the total savings from President Trump’s MFN deals to reach $600 billion over the next decade. DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients, accomplishing historic wins that the political establishment did not believe were possible. On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations. On July 31, 2025, President Trump sent letters to 17 of the leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations. There are now MFN deals with each of those leading pharmaceutical manufacturers. On September 30, 2025, President Trump announced the first agreement, with the drug manufacturer Pfizer, to bring MFN prices to American patients. On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines. On December 19, 2025, President Trump announced nine new agreements with major pharmaceutical companies. On February 5, 2026, President Trump launched TrumpRx.gov , where patients can access large discounts on many of the most popular and highest-priced medicines in the country, paying prices in line with the MFN price. As of today, August 31, the Administration now has agreements with Pfizer, Astra Zeneca, EMD Serono, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, Regeneron, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. President Trump is calling on Congress to enact the Great Healthcare Plan , a comprehensive plan to lower drug prices, lower insurance premiums, hold big insurance companies accountable, and maximize price transparency. Source: Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White House
August 31, 2026
NexGard® Plus donation to Johns Creek Police Department K-9 officers marks the company's commitment to the community. JOHNS CREEK, Ga. (August 31, 2026)– Boehringer Ingelheim today celebrated the grand opening of its new U.S. Animal Health headquarters in Johns Creek, Georgia, marking a significant milestone in the company's commitment to innovation, talent, and the future of animal health. Johns Creek was selected for its access to talent in one of the region's fastest-growing life sciences and innovation corridors, and proximity to other Boehringer sites in Georgia. The grand opening brought together elected officials, community leaders, customers, partners, and employees to celebrate Boehringer's presence in Georgia and its purpose of Transforming Lives for Generations through science and innovation. “The animals we care for and the customers we serve are at the center of everything we do,” said Peter Ploeger, U.S. Animal Health Country Managing Director, Boehringer Ingelheim . “This headquarters was designed to bring our people together, inspire collaboration, and strengthen our ability to develop solutions that improve the lives of companion animals, livestock, and the people who care for them. We are proud to call Johns Creek home and excited about the impact we will create together.” The Johns Creek headquarters complements Boehringer's broader Georgia footprint, which includes research, development, and manufacturing operations in Athens and manufacturing operations in Gainesville. Together, these sites, combining manufacturing, innovation and commercial activities, underline the importance of the U.S. for the company, which continues to invest in Georgia operations to deliver solutions that advance animal health around the world, according to event remarks from Dr. Armin Wiesler, Member of the Board of Managing Directors, Animal Health Business Unit . Georgia and local leaders, including Select Fulton Director of Economic Development Samir Abdullahi, highlighted Boehringer Ingelheim's continued investment in Georgia and commitment to the Johns Creek community. “Georgia continues to attract world-class companies because of our skilled workforce, business-friendly environment, and commitment to innovation,” said Georgia Gov. Brian P. Kemp . “Boehringer Ingelheim's investment in Johns Creek, along with their strong support of First Lady Marty Kemp's animal welfare efforts and K-9 law enforcement officers, reinforces their commitment to being a long-term partner with the State of Georgia." As part of the grand opening celebration, Alexandra McMenamy, U.S. Animal Health, Head of Pet at Boehringer , joined Chief Mitchell and local officials in presenting a donation of NexGard® Plus parasite protection to the Johns Creek Police Department's K-9 Unit in recognition of the department's service to the community. “We are proud to welcome a company committed to the well-being of animals,” said Mayor John Bradberry . “Boehringer Ingelheim’s support of the Johns Creek Police Department’s K-9 Unit is greatly appreciated.” The donation, made just after International Dog Day (August 26), highlights the company's commitment to supporting both animal health and the communities where its employees live and work. 
August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters
MORE POSTS